Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis

doi:10.3748/wjg.v23.i17.3133

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6785)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-6) series.

Item

Count

PDF

510

WORD

288

HTML

3270

Figures (1-5)

224

Tables (1-6)

135

Sum=4427

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

958

Download

1397

Sum=2355

May 7, 2017 (publication date) through May 2, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. May 7, 2017; 23(17): 3133-3141
Published online May 7, 2017. doi: 10.3748/wjg.v23.i17.3133

Table 1 The pathological stage of hepatic fibrosis

Stage	Description	Criteria
S0	No fibrosis	Normal connective tissue
S1	Portal fibrosis	Fibrous portal expansion
S2	Periportal fibrosis	Periportal or rare portal-portal septa
S3	Septal fibrosis	Fibrous septa with architectural distortion; no obvious cirrhosis
S4	Early cirrhosis	Cirrhosis

Citation: Li XM, Chen Z, Xiao EH, Shang QL, Ma C. Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis. World J Gastroenterol 2017; 23(17): 3133-3141
URL: https://www.wjgnet.com/1007-9327/full/v23/i17/3133.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i17.3133